Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

445.32 -10.16 (-2.23%)

Streaming Delayed Price Updated: 12:08 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

68 69 Next >

Vertex Pharmaceuticals Unusual Options Activity ↗

February 03, 2025

Via Benzinga

3 Magnificent Stocks to Buy and Hold Forever ↗

February 03, 2025

Via The Motley Fool

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy? ↗

February 02, 2025

Via The Motley Fool

What You Missed On Friday ↗

February 02, 2025

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.

Via Talk Markets

Topics Stocks / Equities

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ↗

February 02, 2025

Via The Motley Fool

Vertex Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (21 Ratings) ↗

January 30, 2025

Via Benzinga

Is Vertex Pharmaceuticals Stock a Buy in 2025? ↗

January 26, 2025

Via The Motley Fool

Small- To Mid-Cap Biotech Trades Poised For Gains ↗

February 01, 2025

On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these...

Via Talk Markets

Topics ETFs Stocks / Equities

FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief ↗

January 31, 2025

FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate risks of opioids and provide patients with more options.

Via Benzinga

Topics Cannabis

What's going on in today's session: S&P500 movers ↗

January 31, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

Top S&P500 movers in Friday's session ↗

January 31, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Vertex Pharmaceuticals Stock Soars As Non-Opioid Pain Treatment Gets FDA Nod ↗

January 31, 2025

Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing acute pain.

Via Talk Markets

Topics Stocks / Equities

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter ↗

January 31, 2025

The company won Food and Drug Administration approval for its non-opioid painkiller pill on Thursday.

Via Investor's Business Daily

Vertex Pharmaceuticals Shares Are Up Today: What's Going On? ↗

January 31, 2025

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen its position in both pain management and gene therapy.

Via Benzinga

Charter Communications Posts Upbeat Earnings, Joins Atlassian, SkyWest, Eastman Chemical, AbbVie And Other Big Stocks Moving Higher On Friday ↗

January 31, 2025

Via Benzinga

Friday's pre-market session: top gainers and losers in the S&P500 index ↗

January 31, 2025

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

Via Chartmill

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

January 31, 2025

From Vertex Pharmaceuticals

Via Business Wire

Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller ↗

January 30, 2025

The first-in-class drug had suffered a setback in December.

Via Investor's Business Daily

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

January 30, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

This Everest Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

January 30, 2025

Via Benzinga

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10

January 27, 2025

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever. ↗

January 25, 2025

Via The Motley Fool

2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher ↗

January 24, 2025

Via The Motley Fool

MaxCyte: Building the Future of Cell and Gene Therapy Innovation

January 23, 2025

MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.

Via MarketBeat

Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever ↗

January 21, 2025

Via The Motley Fool

8 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2025

Via Benzinga

3 Unstoppable Stocks to Buy in 2025 ↗

January 18, 2025

Via The Motley Fool

HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws' ↗

January 16, 2025

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease.

Via Benzinga

Vertex's Pain Drug: Big Pharma's Next Major Success?

January 16, 2025

Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.

Via MarketBeat

Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30? ↗

January 16, 2025

Via The Motley Fool

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.